APA (7th ed.) Citation

de Almeida, D. V. P., Anderson, J. M., Danila, D. C., Morris, M. J., Slovin, S. F., Abida, W., . . . Autio, K. A. (2023). Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer. Journal of Immunotherapy & Precision Oncology, 6(4), 162. https://doi.org/10.36401/JIPO-23-9

Chicago Style (17th ed.) Citation

de Almeida, Daniel Vargas P., et al. "Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer." Journal of Immunotherapy & Precision Oncology 6, no. 4 (2023): 162. https://doi.org/10.36401/JIPO-23-9.

MLA (9th ed.) Citation

de Almeida, Daniel Vargas P., et al. "Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer." Journal of Immunotherapy & Precision Oncology, vol. 6, no. 4, 2023, p. 162, https://doi.org/10.36401/JIPO-23-9.